Hydrazine sulfate (99%)

Overview

Hydrazine sulfate is an orally active PEPCK inhibitor. Hydrazine sulfate inhibits PEPCK and low- K m ALDH . Hydrazine sulfate impairs gluconeogenesis and enhances the protective effect of energy substrates against MPP + toxicity. Hydrazine sulfate exacerbates liver damage in rats when combined with Ethanol. Hydrazine sulfate can be used in the research of shock, non-small cell lung cancer , colorectal cancer and Parkinson's disease.

Application

Products | Products > Disease Areas > Bacterial Infection | Products > Disease Areas > Neurodegenerative Disease | Products > Disease Areas > Lung Cancer | Products > Disease Areas > Colorectal Cancer | Products > Disease Areas > Digestive System Cancer | Products > Disease Areas > Salmonella Infection | Products > Disease Areas > Parkinson's Disease | Products > Disease Areas > Cancer | Products > Disease Areas > Infection | Products > Disease Areas > Neurological, Eye or Ear Disease | Products > Disease Areas > Digestive System Disease | Products > Disease Areas > Metabolic or Endocrine Disease | Products > Signaling Pathways > Metabolic Enzyme/Protease | Products > Research Areas > Neurological Disease | Products > Research Areas > Metabolic Disease | Products > Research Areas > Cancer | Products > Research Areas > Cancer > Cancer Targeted Therapy | Products > Research Areas > Cancer > Cancer Metabolism and Metastasis | Products > Signaling Pathways > PEPCK | Products > Signaling Pathways > Aldehyde Dehydrogenase (ALDH)

Product Information

• Catalog No.: HY-W115752
• CAS No.: 10034-93-2
• Molecular Formula: H6N2O4S
• Molecular Weight: 130.12
• Purity: 99.16%
• Storage: 4°C, sealed storage, away from moisture * In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
• Solubility: ≥ 0.67 mg/mL (5.15 mM); Clear solution
• Availability: In-stock

Source

Original product source